← Leaderboards
Moira L Aitken
University Of Washington
$48,941
Attributed
$48,941
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$48,941 · 4
By mechanism
M01$48,941 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Anne E Carlson$4,427,969
- Dustin J Maly$15,468,910
- Nancy B. Kiviat$21,349,193
- M Wendy Atkinson$3,864
- Frank A Roberts$542,785
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationClinical ResearchHuman Therapy EvaluationHuman SubjectDosageOral AdministrationDrug Adverse EffectCystic FibrosisLungXanthinesAsthmaPlacebosPyrimidinesQuality Of LifeQuestionnairesRespiratory Disorder ChemotherapyRespiratory FunctionAntiinflammatory AgentsPatient Oriented ResearchMetabolism Disorder ChemotherapyPancreas EnzymeProstaglandin EProstaglandin AnalogsDietary Supplements
Grant awards (11)
A PHASE IIA SAFETY AND EFFICACY STUDY OF ORAL SPI-8811 IN PATIENTS WITH CF$9,985
M01 · FY2005 · RR
Safety and tolerability study of TheraCLEC-total in subjects with CF$25,590
M01 · FY2004 · RR
Phase IIa safety and efficacy study of oral SPI-8811$5,638
M01 · FY2004 · RR
EFFICACY, &METHODOLOGY STUDY IN ATOPIC PTS W/ ASTHMA$0
M01 · FY2002 · RR
ORAL MULTIDOSE CPX IN ADULT PTS W/ MILD TO SEVERE CF$0
M01 · FY2002 · RR
EFFICACY, &METHODOLOGY STUDY IN ATOPIC PTS W/ ASTHMA$0
M01 · FY2001 · RR
ORAL MULTIDOSE CPX IN ADULT PTS W/ MILD TO SEVERE CF$0
M01 · FY2001 · RR
PHASE II TRIAL OF ORAL MULTIDOSE CPX IN ADULT PATIENTS W/ MILD TO CF$3,864
M01 · FY2000 · RR
MULTIPLE ORAL DOSE SAFETY, EFFICACY, &METHODOLOGY STUDY IN ATOPIC$3,864
M01 · FY2000 · RR
EFFICACY, &METHODOLOGY STUDY IN ATOPIC PTS W/ ASTHMA$0
M01 · FY2000 · RR
ORAL MULTIDOSE CPX IN ADULT PTS W/ MILD TO SEVERE CF$0
M01 · FY2000 · RR